Jun 10, 2021 / 01:40PM GMT
Andrea R. Tan - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone. Thanks for joining us on the last day of our conference. I'm Andrea Tan, biotech analyst at Goldman Sachs. And I'm pleased to have with us the team from Madrigal, Paul Friedman, CEO; Becky Taub, CMO and President of R&D; Remy Sukhija, CCO; and newly appointed CFO, Alex Howarth. With that, maybe, Paul, I'll start with you and turn it over for opening remarks.
Paul A. Friedman - Madrigal Pharmaceuticals, Inc. - Chairman & CEO
Sure. Andrea, we're pleased to be here. Appreciate your recent positive coverage of Madrigal. For those of you who may not be familiar with Madrigal, before beginning the Q&A, we have a few high-level slides to share as a brief introduction to our company and resmetirom, our liver-directed thyroid receptor beta agonist.
Can we see Slide 2, please? Okay. So this is our fine print regarding forward-looking statements, and you can peruse it at your leisure.
Next slide. To begin, Madrigal has an experienced
Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers